Theriva Biologics has completed the design of a proposed Phase 2/3 study evaluating intravitreal VCN-01 with intravitreal topotecan in children whose retinoblastoma with vitreous seeds remains refractory or resistant to existing intravitreal chemotherapy. The company plans to discuss the protocol with the United States Food and Drug Administration during the third quarter of 2026, potentially establishing a more direct late-stage development path for an oncolytic adenovirus that has so far been tested in only nine children with advanced disease.
The planned study is based on encouraging but highly preliminary Phase 1 findings. In that investigator-sponsored trial, four of nine evaluable patients showed unequivocal improvement in vitreous seed density, while eye removal had been avoided in three patients at the time of the company’s follow-up, including one child who had retained the treated eye after four years. The early study primarily assessed safety and tolerability, so those observations cannot establish how reliably VCN-01 preserves eyes or controls cancer in a larger population.
Proposed Phase 2/3 design could shorten the path from early proof of concept to pivotal testing
Theriva Biologics said it developed the proposed Phase 2/3 protocol after extensive discussions with key opinion leaders and intends to seek FDA feedback before advancing the program. The study would combine intravitreal VCN-01 with intravitreal topotecan in children whose vitreous disease has failed or resisted currently available intravitreal chemotherapy, a population for which treatment options can narrow to removal of the affected eye when local control cannot be achieved.
Moving from a nine-patient Phase 1 study into a combined Phase 2/3 design would represent a substantial acceleration in development. Such a structure could allow an earlier portion of the study to refine efficacy and safety assumptions before seamlessly expanding into a more definitive population, although the final design, endpoints, enrollment target and statistical plan will depend on regulatory discussions. Theriva Biologics has not yet disclosed those details, making it premature to characterize the proposed study as registrational until the FDA provides feedback.
The regulatory environment offers some support. VCN-01 holds Orphan Drug designation from both the FDA and European Medicines Agency for retinoblastoma and also has FDA Rare Pediatric Disease designation. Theriva Biologics said that if a Biologics License Application for VCN-01 in retinoblastoma receives FDA approval by September 30, 2029, the company could potentially qualify for a Priority Review Voucher under the applicable program.
That possible voucher adds a financial incentive to rapid development, but the deadline also creates execution pressure. Theriva would need to finalize the protocol, begin and complete an adequately informative trial, prepare a biologics application and secure approval within roughly three years. Whether that timetable is feasible will depend on FDA feedback, recruitment in an ultra-rare pediatric population, manufacturing readiness and the company’s ability to finance the study.
Phase 1 data offer an eye-preservation signal but remain far too small to establish efficacy
The earlier Phase 1 study enrolled nine pediatric patients with intraocular retinoblastoma that had become refractory to chemotherapy or radiotherapy and for whom enucleation was the recommended remaining treatment. Participants received two VCN-01 injections directly into the vitreous cavity 14 days apart, with one patient receiving 2 × 10⁹ viral particles per eye and eight receiving 2 × 10¹⁰ viral particles per eye.
The study monitoring committee considered the trial outcome positive. Theriva Biologics reported no dose-limiting toxicities and no Grade 3 or higher ocular or systemic toxicities during the evaluation period. The most frequent treatment-related effects were Grade 1 or Grade 2, although some children developed ocular inflammation and vitreous turbidity after injection that required local or systemic anti-inflammatory treatment.
Four children showed what the company described as unequivocal improvement in vitreous seed density. Three had avoided enucleation at the reported follow-up, while one had retained the affected eye for four years. These findings are clinically meaningful enough to support further investigation because eye preservation is an important treatment objective after survival has been secured, but the uncontrolled nine-patient study cannot determine how much of the observed benefit resulted from VCN-01 or how consistently it would occur alongside topotecan.
Retinoblastoma is the most common eye cancer of childhood and typically appears in very young children. Theriva Biologics cites an incidence of approximately one case per 14,000 to 18,000 live births and roughly 200 to 300 diagnoses annually in the United States. The rarity creates both regulatory opportunity and clinical-development difficulty because recruiting a sufficiently informative trial can require cooperation across specialized pediatric oncology centers and multiple countries.
VCN-01 is designed to attack tumor cells while making resistant cancers easier to treat
VCN-01 is an oncolytic adenovirus engineered to selectively replicate within cancer cells and disrupt the tumor stroma, the physical and immunosuppressive environment surrounding many tumors. Theriva Biologics says the mechanism is intended to produce direct tumor-cell killing, improve access for accompanying anticancer treatments and expose malignant tissue more effectively to immune attack.
In retinoblastoma, VCN-01 is delivered directly into the vitreous rather than intravenously. The proposed Phase 2/3 trial would pair that local viral treatment with topotecan, creating a strategy in which VCN-01 could potentially weaken resistant tumor deposits while chemotherapy provides an additional cytotoxic effect. The clinical value of that combination has not yet been established because the Phase 1 study evaluated VCN-01 without the proposed pivotal regimen.
Theriva is also developing VCN-01 across several other cancers. First patients have been dosed in the six-patient VIRAGE2 Phase 2a study testing more frequent repeated intravenous administration with gemcitabine and nab-paclitaxel in newly diagnosed metastatic pancreatic ductal adenocarcinoma, while Phase 1 findings in immunotherapy-refractory head and neck squamous cell carcinoma have supported additional interest in the virus as a tumor-stroma and immune-modifying agent.
Those programs give Theriva multiple opportunities to validate VCN-01’s mechanism, but the indications have different routes of administration, disease biology and treatment combinations. Success in pancreatic or head and neck cancer would not automatically predict efficacy inside the eye, while positive retinoblastoma results would not establish systemic effectiveness elsewhere.
Theriva’s $11.3 million cash balance makes financing a major constraint on the proposed trial
Theriva Biologics ended June with $11.3 million in cash and cash equivalents and said its current resources were expected to support operations into the first quarter of 2027. The balance declined from $13.1 million at the end of 2025, while the company recorded a net loss of approximately $5.3 million during the first six months of 2026.
Second-quarter research and development expenses totaled $1.3 million, down from $2 million a year earlier, but spending could rise materially if Theriva progresses a multi-center Phase 2/3 pediatric oncology study while also continuing VIRAGE2 and manufacturing work for VCN-01. The company itself identifies its ability to raise capital, obtain development funding or secure partnerships as factors that could affect planned clinical development.
Theriva Biologics shares were trading near $0.23 on August 11, with a market capitalization of approximately $9.4 million. The extremely small valuation and short stated cash runway indicate that financing risk remains tightly linked to the clinical story, even if FDA discussions produce a favorable Phase 2/3 framework.
The upcoming FDA meeting is therefore more than a procedural milestone. A clearly defined late-stage path could improve Theriva’s ability to seek outside capital or a development partner by establishing how much evidence is required, how many patients may need to be recruited and whether the trial could support a future biologics application.
The Phase 1 findings justify taking that discussion forward, particularly because several children with otherwise treatment-resistant disease showed reduced vitreous tumor burden and avoided eye removal. The next study must establish whether those observations can be reproduced prospectively and safely when VCN-01 is combined with topotecan. Until then, the proposed Phase 2/3 program represents a promising route toward eye-preserving treatment rather than evidence that VCN-01 has already solved the therapeutic problem.
